Cargando…

Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients

Background: The purpose of our study was to characterize clinical features among brain metastasis (BM) patients who were long term survivors (LTS). Methods: We reviewed a registry of BM patients referred to our multidisciplinary BM clinic between 2006 and 2014 and identified 97 who lived ≥ 3 years f...

Descripción completa

Detalles Bibliográficos
Autores principales: Dasgupta, Archya, Co, Jayson, Winter, Jeff, Millar, Barbara-Ann, Laperriere, Normand, Tsang, Derek S., van Prooijen, Monique, Damyanovich, Andrei, Heaton, Robert, Coolens, Catherine, Bernstein, Mark, Kongkham, Paul, Zadeh, Gelareh, Berlin, Alejandro, Conrad, Tatiana, Moraes, Fabio Y., Shultz, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903267/
https://www.ncbi.nlm.nih.gov/pubmed/33477698
http://dx.doi.org/10.3390/curroncol28010054
_version_ 1783654699652612096
author Dasgupta, Archya
Co, Jayson
Winter, Jeff
Millar, Barbara-Ann
Laperriere, Normand
Tsang, Derek S.
van Prooijen, Monique
Damyanovich, Andrei
Heaton, Robert
Coolens, Catherine
Bernstein, Mark
Kongkham, Paul
Zadeh, Gelareh
Berlin, Alejandro
Conrad, Tatiana
Moraes, Fabio Y.
Shultz, David B.
author_facet Dasgupta, Archya
Co, Jayson
Winter, Jeff
Millar, Barbara-Ann
Laperriere, Normand
Tsang, Derek S.
van Prooijen, Monique
Damyanovich, Andrei
Heaton, Robert
Coolens, Catherine
Bernstein, Mark
Kongkham, Paul
Zadeh, Gelareh
Berlin, Alejandro
Conrad, Tatiana
Moraes, Fabio Y.
Shultz, David B.
author_sort Dasgupta, Archya
collection PubMed
description Background: The purpose of our study was to characterize clinical features among brain metastasis (BM) patients who were long term survivors (LTS). Methods: We reviewed a registry of BM patients referred to our multidisciplinary BM clinic between 2006 and 2014 and identified 97 who lived ≥ 3 years following BM diagnosis. The clinical and treatment characteristics were obtained from a prospectively maintained database, and additional information was obtained through review of electronic medical records and radiologic images. Survival analyses were performed using the Kaplan-Meier method. Results: Median follow up for LTS was 67 months (range 36–181). Median age was 54 years, 65% had single BM, 39% had stable extracranial disease at the time of BM treatment, and brain was the first site of metastasis in 76%. Targetable mutations were present in 39% of patients and 66% received treatment with targeted-, hormonal-, or immuno-therapy. Brain surgery at the time of diagnosis was performed in 40% and stereotactic radiosurgery (SRS) or whole brain radiotherapy (alone or combination) in 52% and 56%, respectively. Following initial BM treatment, 5-year intracranial disease-free survival was 39%, and the cumulative incidence of symptomatic radio-necrosis was 16%. Five and ten-year overall survival was 72% and 26%, respectively. Conclusion: Most LTS were younger than 60 years old and had a single BM. Many received treatment with surgery or targeted, immune, or hormonal therapy.
format Online
Article
Text
id pubmed-7903267
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79032672021-02-25 Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients Dasgupta, Archya Co, Jayson Winter, Jeff Millar, Barbara-Ann Laperriere, Normand Tsang, Derek S. van Prooijen, Monique Damyanovich, Andrei Heaton, Robert Coolens, Catherine Bernstein, Mark Kongkham, Paul Zadeh, Gelareh Berlin, Alejandro Conrad, Tatiana Moraes, Fabio Y. Shultz, David B. Curr Oncol Article Background: The purpose of our study was to characterize clinical features among brain metastasis (BM) patients who were long term survivors (LTS). Methods: We reviewed a registry of BM patients referred to our multidisciplinary BM clinic between 2006 and 2014 and identified 97 who lived ≥ 3 years following BM diagnosis. The clinical and treatment characteristics were obtained from a prospectively maintained database, and additional information was obtained through review of electronic medical records and radiologic images. Survival analyses were performed using the Kaplan-Meier method. Results: Median follow up for LTS was 67 months (range 36–181). Median age was 54 years, 65% had single BM, 39% had stable extracranial disease at the time of BM treatment, and brain was the first site of metastasis in 76%. Targetable mutations were present in 39% of patients and 66% received treatment with targeted-, hormonal-, or immuno-therapy. Brain surgery at the time of diagnosis was performed in 40% and stereotactic radiosurgery (SRS) or whole brain radiotherapy (alone or combination) in 52% and 56%, respectively. Following initial BM treatment, 5-year intracranial disease-free survival was 39%, and the cumulative incidence of symptomatic radio-necrosis was 16%. Five and ten-year overall survival was 72% and 26%, respectively. Conclusion: Most LTS were younger than 60 years old and had a single BM. Many received treatment with surgery or targeted, immune, or hormonal therapy. MDPI 2021-01-18 /pmc/articles/PMC7903267/ /pubmed/33477698 http://dx.doi.org/10.3390/curroncol28010054 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dasgupta, Archya
Co, Jayson
Winter, Jeff
Millar, Barbara-Ann
Laperriere, Normand
Tsang, Derek S.
van Prooijen, Monique
Damyanovich, Andrei
Heaton, Robert
Coolens, Catherine
Bernstein, Mark
Kongkham, Paul
Zadeh, Gelareh
Berlin, Alejandro
Conrad, Tatiana
Moraes, Fabio Y.
Shultz, David B.
Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients
title Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients
title_full Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients
title_fullStr Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients
title_full_unstemmed Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients
title_short Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients
title_sort clinicopathologic and treatment features of long-term surviving brain metastasis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903267/
https://www.ncbi.nlm.nih.gov/pubmed/33477698
http://dx.doi.org/10.3390/curroncol28010054
work_keys_str_mv AT dasguptaarchya clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT cojayson clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT winterjeff clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT millarbarbaraann clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT laperrierenormand clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT tsangdereks clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT vanprooijenmonique clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT damyanovichandrei clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT heatonrobert clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT coolenscatherine clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT bernsteinmark clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT kongkhampaul clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT zadehgelareh clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT berlinalejandro clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT conradtatiana clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT moraesfabioy clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients
AT shultzdavidb clinicopathologicandtreatmentfeaturesoflongtermsurvivingbrainmetastasispatients